Catalog No.
YHG07801
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Arg28-Thr184
Predicted molecular weight
20.78 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q06187
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
BPK, Tyrosine-protein kinase BTK, AGMX1, Agammaglobulinemia tyrosine kinase, Bruton tyrosine kinase, BTK, ATK, B-cell progenitor kinase
Covalent Recruitment of NEDD4 for Targeted Protein Degradation: Rational Design of Small Molecular Degraders., PMID:40506832
Acoustic ejection mass spectrometry: An integrated pipeline for ultra-high throughput screening, reactivity profiling, and potency analysis of covalent BTK inhibitors., PMID:40505495
Uncovering the mechanism of Buyang Huanwu decoction in regulating mitochondrial dysfunction to alleviate atherosclerosis: BTK, PREPL, and P2RX7 proteins play key roles., PMID:40494461
Antibody-Directed Cell Internalization of Targeted Covalent Europium Tag Enables In Situ Kinase Labeling and Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Quantification., PMID:40470552
Proteome-wide Ligand and Target Discovery by Using β-Nitrostyrene Electrophiles: Supporting Targeted Protein Degradation., PMID:40464197
Phosphorylation-inducing molecules for regulating dynamic cellular processes., PMID:40462997
Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization., PMID:40461100
Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells., PMID:40445239
The role of microglia in multiple sclerosis: implications for treatment with Bruton's tyrosine kinase inhibitors., PMID:40443664
Bruton Tyrosine Kinase in Lesions of Multiple Sclerosis and 3 of Its Models., PMID:40440578
Bruton's Tyrosine Kinase: A Potential Novel Target for Neurological Disorders., PMID:40432438
Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma., PMID:40421905
Rapamycin-modified CD169low/-tolDC promotes skin graft survival in mice via IL-10+Breg., PMID:40414462
Benchmarking of pH-responsive mixed micelles for repurposed breast cancer therapy of ibrutinib with molecular modeling and pharmacokinetic insights., PMID:40401393
Structure-based design of novel pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives as potent noncovalent Bruton's tyrosine kinase (BTK) inhibitors., PMID:40398523
Discovery of IHMT-15130 as a Highly Potent Irreversible BMX Inhibitor for the Treatment of Myocardial Hypertrophy and Remodeling., PMID:40388356
Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence., PMID:40385351
Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases., PMID:40378821
USP11 Promotes Endothelial Apoptosis-Resistance in Pulmonary Arterial Hypertension by Deubiquitinating HINT3., PMID:40376595
Computational insights into mutation-induced binding changes in Bruton's Tyrosine Kinase with non-covalent inhibitors., PMID:40372209
Discovery of Imidazo[1,2-b]pyridazine Derivatives as Potent and Highly Selective Irreversible Bruton's Tyrosine Kinase (BTK) Inhibitors., PMID:40369903
Transcriptomic profiling in canine B-cell lymphoma supports a synergistic effect of BTK and PI3K inhibitors., PMID:40351764
A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network., PMID:40341807
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies., PMID:40335884
New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies., PMID:40332536
Synthesis of a Potent Bruton's Tyrosine Kinase Inhibitor Labelled With Carbon-14 and Deuterium., PMID:40323715
The importance of TP53 status in cancer therapy: The example of chronic lymphocytic leukemia., PMID:40321704
Chronic lymphocytic leukemia: what clinical progress have we seen in the last five years?, PMID:40314223
Acalabrutinib alleviates metabolic dysfunction-associated steatotic liver disease by regulating bile acid metabolism., PMID:40306481
Wnt5a induces ROR1 dependent NF-κB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia., PMID:40295829
Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma., PMID:40278919
Immune therapies in coeliac disease and food allergies: Advances, challenges, and opportunities., PMID:40273881
Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials., PMID:40272546
Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial., PMID:40266575
Evobrutinib mitigates neuroinflammation after ischemic stroke by targeting M1 microglial polarization via the TLR4/Myd88/NF-κB pathway., PMID:40263985
Critical roles of chronic BCR signaling in the differentiation of anergic B cells into age-associated B cells in aging and autoimmunity., PMID:40249819
Activin B improves glucose metabolism via induction of Fgf21 and hepatic glucagon resistance., PMID:40246973
Double Strike in Chronic Lymphocytic Leukemia-The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice., PMID:40243993
Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures., PMID:40242575
The t(18;22)/IGL::BCL2 translocation defines a unique CLL subtype: association with early treatment initiation., PMID:40240735
Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis., PMID:40234394
Rilzabrutinib for the Treatment of Immune Thrombocytopenia., PMID:40222822
UBE2N modulates osteoclast differentiation via BTK-PLCγ2-Ca2+ signaling pathway to promote osteoporosis., PMID:40220977
AMPLIFY: A second-generation BTK inhibitor for fixed-duration therapy in chronic lymphocytic leukemia., PMID:40220751
Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis., PMID:40203277
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis., PMID:40202623
Design, Synthesis, and Biological Evaluation of Pyrrolo[1,2-a]quinoxalin-4(5H)-one Derivatives as Potent and Orally Available Noncovalent Bruton's Tyrosine Kinase (BTK) Inhibitors., PMID:40191988
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia., PMID:40179394
Current and emerging treatment perspectives for adults with Waldenström macroglobulinemia., PMID:40176471
Click Chemistry for Target Engagement Studies., PMID:40163305
For research use only. Not for human or drug use.
